about
Telomere shortening in Down syndrome patients--when does it start?The tetramethoxyflavone zapotin selectively activates protein kinase C epsilon, leading to its down-modulation accompanied by Bcl-2, c-Jun and c-Fos decrease.Strain-dependent mutational effects for Pepino mosaic virus in a natural host.Telomere length assessment in leukocytes presents potential diagnostic value in patients with breast cancerTelomerase downregulation induces proapoptotic genes expression and initializes breast cancer cells apoptosis followed by DNA fragmentation in a cell type dependent mannerHuman telomerase activity regulation.Telomerase modulation in therapeutic approach.Spectroscopic study and G-quadruplex DNA binding affinity of two bioactive papaverine-derived ligands.Semisynthetic oleanane triterpenoids inhibit migration and invasion of human breast cancer cells through downregulated expression of the ITGB1/PTK2/PXN pathway.Formaldehyde Is a Potent Proteotoxic Stressor Causing Rapid Heat Shock Transcription Factor 1 Activation and Lys48-Linked Polyubiquitination of Proteins.Proapoptotic activity and ABCC1-related multidrug resistance reduction ability of semisynthetic oleanolic acid derivatives DIOXOL and HIMOXOL in human acute promyelocytic leukemia cells.Telomerase and drug resistance in cancer.Oleanolic acid derivative methyl 3,11-dioxoolean-12-en-28-olate targets multidrug resistance related to ABCB1.The biological activity of G-quadruplex DNA binding papaverine-derived ligand in breast cancer cells.Analysis of expression of MHC class I molecules and TAP genes in malignant human cell lines.Arginine vasopressin stimulates 11beta-hydroxysteroid dehydrogenase type 2 expression in the mineralocorticosteroid target cells.Contribution of protein kinase A and protein kinase C signalling pathways to the regulation of HSD11B2 expression and proliferation of MCF-7 cells.Universal real-time PCR-based assay for lentiviral titration.Phytosterols in physiological concentrations target multidrug resistant cancer cells.Accumulation of environmental estrogens in adipose tissue of breast cancer patients.Studies on CYP1A1, CYP1B1 and CYP3A4 gene polymorphisms in breast cancer patients.Bystander senescence in human peritoneal mesothelium and fibroblasts is related to thrombospondin-1-dependent activation of transforming growth factor-β1.Beneficial or harmful influence of phytosterols on human cells?hTERT gene knockdown enhances response to radio- and chemotherapy in head and neck cancer cell lines through a DNA damage pathway modification.Study of ABCB1 polymorphism frequency in breast cancer patients from Poland.hTERT C250T promoter mutation and telomere length as a molecular markers of cancer progression in patients with head and neck cancer.Smith-Lemli-Opitz syndrome - clinical consequences for dental careSerum from patients with chronic obstructive pulmonary disease induces senescence-related phenotype in bronchial epithelial cellsPolymorphism of the Porcine Leptin Gene Promoter and Analysis of Its Association with Gene Expression and Fatness TraitsBinding Study of the Fluorescent Carbazole Derivative with Human Telomeric G-Quadruplexes.The non-canonical functions of telomerase: to turn off or not to turn offImpact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolitesThe influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseasesDAT1 methylation changes in alcohol-dependent individuals vs. controlsVitamin C as a Modulator of the Response to Cancer TherapyVitamin C increases DNA breaks and suppresses DNA damage-independent activation of ATM by bleomycinThe use of split-thickness dermal grafts to resurface full thickness skin defects[siRNA targeting telomerase--effective tool in anti-cancer therapy?]Murine double minute clone 2,309T/G and 285G/C promoter single nucleotide polymorphism as a risk factor for breast cancer: a Polish experienceCXCL12-3' G801A polymorphism is not a risk factor for breast cancer
P50
Q35794673-2939819E-C606-4F17-9098-A626AC87F5C2Q35866974-5D772234-F013-43B9-817E-F9CE2D671402Q36298674-18510173-1827-4AC6-800C-435CAFE2E873Q36640809-99173E59-700F-4F25-B9FB-FD573FEDC560Q37046392-6873E7ED-BBFD-4AC8-B9BC-2DDFAD699004Q37810521-29AF1DE0-2EDC-44C5-A9CA-29A276650BABQ38224274-FE34F2EB-9ED5-4AEA-870F-A898624B3C90Q38298947-C768983A-38E5-46C3-840A-B5B2462F18A8Q38711374-66C27258-96AC-42A8-87B8-7B8083EC8C47Q38736079-C1A28971-096E-4C12-90B6-1ACA01D78C2EQ38835955-ED192E2C-C7A6-4F7D-8BD4-17D2E2CBA016Q39379394-DE45C3CB-8A99-47DE-8117-10940A6020B4Q39391831-414BF4A0-EA1F-4737-A899-700F07794A71Q39942960-10A66A11-B99C-4753-8A24-36AD3B1B4040Q40064613-BEB9E332-B65F-40B2-9343-6857C81C3826Q40250826-B75B56C9-28D8-4928-AC39-856EB134F8CBQ40476103-59401FCF-4B3E-47A1-8A4A-12A2864B7AABQ42182178-993087C1-186B-481C-B13B-CFA06298BAFCQ42477053-93575963-3702-4A46-876C-A47490538C0DQ43100282-0AF3CFC1-D62D-4E32-8716-F6075CD73BA7Q43188862-7A8F7C22-8F98-4562-A5AE-BC57BBF9A97EQ46211099-DCA8AED8-0884-466C-8BA6-8FEB317FA9DBQ46620205-7A542771-A9A7-4E20-8B04-8DEAEDCA50ADQ52589078-5C58CFE0-C02B-4294-98FC-95D0524B2A6AQ52638206-2D186395-22F4-4F0B-A207-C78C16D7B805Q52641991-A1108E24-5701-4E2E-83BE-4440B7FBEECEQ57147727-BDDB2E5E-FD1D-41B7-B4C3-391DE98334E7Q58699427-4E626FEA-F50E-4C68-B019-4713E518C536Q58825688-A972210F-DF33-4841-BA2C-3CFA4904CD7BQ60112354-D3B109EB-D755-4872-99BF-E850DA5BEC55Q60112361-101F6A7C-2829-4E74-85DD-801F56124547Q61537077-BD0C5F20-0767-4563-A68E-45FE9B1EE232Q61537083-0BDC907E-0EBD-40B5-A6EC-6E4A4E2D1A3FQ61945838-96B37A96-EC1C-4638-B24C-011C270A1602Q64268237-F2FB6345-9B07-41DF-8EE2-CF9B435928F9Q64387425-D3E5DEDE-09A9-4FFC-B800-F6750572EB14Q78607968-36E0FB4C-A92B-4BD9-93DD-AEA5FC533197Q83400121-5DDBEAEE-C628-417B-8D42-4C87EA935CB1Q83786389-D5738F18-E848-463F-A1B2-554F288C036FQ84080234-8315EB22-5E9A-4FF7-8500-66FF88BDA0BF
P50
description
Pools onderzoeker
@nl
researcher ORCID ID = 0000-0003-1730-0176
@en
name
Blazej Rubis
@ast
Blazej Rubis
@en
Blazej Rubis
@es
Blazej Rubis
@nl
Błażej Rubiś
@ca
Błażej Rubiś
@cs
Błażej Rubiś
@gl
Błażej Rubiś
@hr
Błażej Rubiś
@hsb
Błażej Rubiś
@it
type
label
Blazej Rubis
@ast
Blazej Rubis
@en
Blazej Rubis
@es
Blazej Rubis
@nl
Błażej Rubiś
@ca
Błażej Rubiś
@cs
Błażej Rubiś
@gl
Błażej Rubiś
@hr
Błażej Rubiś
@hsb
Błażej Rubiś
@it
altLabel
Błażej Rubiś
@en
prefLabel
Blazej Rubis
@ast
Blazej Rubis
@en
Blazej Rubis
@es
Blazej Rubis
@nl
Błażej Rubiś
@ca
Błażej Rubiś
@cs
Błażej Rubiś
@gl
Błażej Rubiś
@hr
Błażej Rubiś
@hsb
Błażej Rubiś
@it
P106
P108
P1412
P1559
Błażej Rubiś
@pl
P21
P27
P31
P3124
P496
0000-0003-1730-0176